Long-term outcome in polymyositis and dermatomyositis

Annals of the Rheumatic Diseases

Volumn 65, Issue 11, 2006, Pages 1456-1461

  Bronner, I M ^a   Van Der Meulen, M F G ^b   De Visser, M ^a   Kalmijn, S ^b   Van Venrooij, W J ^c   Voskuyl, A E ^d   Dinant, H J ^e   Linssen, W H J P ^f   Wokke, J H J ^b   Hoogendijk, J E ^b  

^a UNIVERSITY OF AMSTERDAM   (Netherlands)

^b UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^c RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^d VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^e ACADEMIC MEDICAL CENTER   (Netherlands)

^f ONZE LIEVE VROUWE GASTHUIS   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

AZATHIOPRINE; CYCLOPHOSPHAMIDE; CYCLOSPORIN; IMMUNOGLOBULIN; IMMUNOMODULATING AGENT; IMMUNOSUPPRESSIVE AGENT; METHOTREXATE; PREDNISONE;

ACNE; ADOLESCENT; ADULT; AGED; ARTICLE; ASEPTIC NECROSIS; CANCER; CATARACT; CONNECTIVE TISSUE DISEASE; CONTROLLED STUDY; CUSHING DISEASE; DERMATOMYOSITIS; DISEASE COURSE; FEMALE; FOLLOW UP; GLAUCOMA; HUMAN; HYPERGLYCEMIA; HYPERTENSION; INFECTION; LONG TERM CARE; LUNG DISEASE; MAJOR CLINICAL STUDY; MALE; MENTAL DISEASE; MORTALITY; MUSCLE WEAKNESS; OSTEOPOROSIS; PHYSICAL DISABILITY; PLASMAPHERESIS; POLYMYOSITIS; PRIORITY JOURNAL; PROGNOSIS; REMISSION; RISK ASSESSMENT; STRENGTH; SURVIVAL; TREATMENT OUTCOME;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; AUTOANTIBODIES; DERMATOMYOSITIS; DISABILITY EVALUATION; DISEASE PROGRESSION; FEMALE; FOLLOW-UP STUDIES; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MALE; MIDDLE AGED; POLYMYOSITIS; PROGNOSIS; QUALITY OF LIFE; SURVIVAL ANALYSIS;

EID: 33750306690     PISSN: 00034967     EISSN: None     Source Type: Journal    
DOI: 10.1136/ard.2005.045690     Document Type: Article

References (40)

1. DeVere R, Bradley WG. Polymyositis: its presentation, morbidity and mortality. Brain 1975;98:637-66.
2. Bohan A, Peter JB, Bowman RL, Pearson CM. A computer-assisted analysis of 153 patients with polymyositis and dermatomyositis. Medicine 1977;56:255-83.
3. Carpenter JR, Bunch TW, Engel AG, O'Brien PC. Survival in polymyositis: corticosteroids and risk factors. J Rheumatol 1977;4:207-14.
4. Henriksson KG, Sandstedt P. Polymyositis-treatment and prognosis. A study of 107 patients. Acta Neurol Scand 1982;65:280-300.
5. Tymms KE, Webb J. Dermatopolymyositis and other connective tissue diseases: a review of 105 cases. J Rheumatol 1985;12:1140-8.
6. Hochberg MC, Feldman D, Stevens MB. Adult onset polymyositis/ dermatomyositis: an analysis of clinical and laboratory features and survival in 76 patients with a review of the literature. Semin Arthritis Rheum 1986;15:168-78.
7. Chwalinska-Sadowska H, Maldykowa H. Polymyositis-dermatomyositis: 25 years of follow-up of 50 patients disease course, treatment, prognostic factors. Mat Med Polona 1990;3:213-18.
8. Love LA, Leff RL, Fraser DD, Targoff IN, Dalakas M, Plotz PH, et al. A new approach to the classification of idiopathic inflammatory myopathy: myositis-specific autoantibodies define useful homogeneous patient groups. Medicine 1991;70:360-74.
9. Fafalak RG, Peterson MGE, Kagen LJ. Strength in polymyositis and dermatomyositis: best outcome in patients treated early. J Rheumatol 1994;21:643-8.
10. Maugars YM, Berthelot JMM, Abbas AA, Mussinin JMD, Nguyen JMD, Prost AM. Long-term prognosis of 69 patients with dermatomyositis or polymyositis. Clin Exp Rheum 1996;14:263-74.
11. Marie I, Hachulla E, Hatron PY, Hellot MF, Levesque H, Devulder B, et al. Polymyositis and dermatomyositis: short term and long term outcome, and predictive factors of prognosis. J Rheumatol 2001;28:2230-7.
12. Chung YL, Mitchell HL, Houssien DA, Al-Mahrouki H, Carr AJ, Scott DL. A comparative study of outcome in myositis and other musculoskeletal disorders assessed using the Nottingham Health Profile. Clin Exp Rheumatol 2001;19:447-50.
13. Hengstman GJD, Brouwer R, Vree Egberts WTM, Seelig HP, Jongen PJ, van Venrooij WJ, et al. Clinical and serological characteristics of 125 Dutch myositis patients. J Neurol 2002;249:69-75.
14. Danko K, Ponyi A, Constantin T, Borgulya G, Szegedi G. Long term survival of patients with idiopathic inflammatory myoapathies according to clinical features. A longitudinal study of 162 cases. Medicine 2004;83:35-42.
15. Ponyi A, Borgula G, Constantin T, Vancsa A, Gergely L, Danko K. Functional outcome and quality of life in adults with idiopathic inflammatory myositis. Rheumatology 2005;44:83-8.
16. van der Meulen MF, Hoogendijk JE, Jansen GH, Veldman H, Wokke JH. Absence of characteristic features in two patients with inclusion body myositis. J Neurol Neurosurg Psychiatry 1998;64:396-8.
17. Griggs RC, Askanas V, DiMauro S, Engel A, Karpati G, Mendell JR, et al. Inclusion body myositis and myopathies. Ann Neurol 1995;38:705-13.
18. van der Meulen MFG, Bronner IM, Hoogendijk JE, Burger H, van Venrooij WJ, Voskuyl AE, et al. Polymyositis: an overdiagnosed entity. Neurology 2003;61:316-21.
19. Arahata K, Engel AG. Monoclonal antibody analysis of mononuclear cells in myopathies. I: quantitation of subsets according to diagnosis and sites of accumulation and demonstration and counts of muscle fibers invaded by T cells. Ann Neurol 1984;16:193-208.
20. Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS, et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988;31:315-24.
21. Tan EM, Cohen AS, Fries JF, Masi AT, McShane DJ, Rothfield NF, et al. The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1982;25:1271-7.
22. Vitali C, Bombardieri S, Moutsopoulos HM, Jonsson R, Moutsopoulos HM, Alexander EL, et al. Assessment of the European classification criteria for Sjögren's syndrome in a series of clinically defined cases: results of a prospective multicentre study. The European Study Group on Diagnostic Criteria for Sjögren's Syndrome. Ann Rheum Dis 1996;55:116-21.
23. Subcommittee for Scleroderma Criteria of the American Rheumatism Association Diagnostic and Therapeutic Criteria Committee. Preliminary criteria for the classification of systemic sclerosis (scleroderma). Arthritis Rheum 1980;23:581-90.
24. Kasukawa R. Mixed connective tissue disease. Intern Med 1999;38:386-93.
25. Buchbinder R, Forbes A, Hall S, Dennet X, Giles G. Incidence of malignant disease in biopsy-proven inflammatory myopathy. A population based cohort study. Ann Intern Med 2001;134:1087-95.
26. Brouwer R, Hengstman GJ, Vree Egberts W, Ehrfeld H, Bozic B, Ghirardello A, et al. Autoantibody profiles in the sera of European patients with myositis. Ann Rheum Dis 2001;60:116-23.
27. Notermans NC, Wokke JHJ, Fransen H, van der Graaf Y, Vermeulen M, van den Berg LH, et al. Chronic idiopathic polyneuropathy presenting in middle or old age: a clinical and electrophysiological study of 75 patients. J Neurol Neurosurg Psychiatry 1993;56:1066-71.
28. Swieten JC van, Koudstaal PJ, Visser MC, Scouten HJA, van Gijn J. Interobserver agreement for the assessment of handicap in stroke patients. Stroke 1988;19:604-7.
29. Berger M, Bobbitt RA, Carter WB, Gilson BS. The Sickness Impact Profile: development and final revision of a health status measure. Med Care 1981;19:787-805.
30. Read JL, Quinn RJ, Hoefer MA. Measuring overall health: an evaluation of three important approaches. J Chromi Dis 1987;40(Suppl 1):S7-21.
31. Jacobs HM, Luttik A, Touw-Otten FWMM, de Melker RA. The Sickness Impact Profile; results of a validation study of the Dutch version. Ned Tijdschr Geneeskd 1990;134:1950-4.
32. Huber AM, Lang B, LeBlanc CMA, Birdi N, Bolaria RK, Malleson P, et al. Medium- and long-term functional outcomes in a multicenter cohort of children with juvenile dermatomyositis. Arthritis Rheum 2000;43:541-9.
33. Van Houwelingen JC, Le Cessie S. Predictive value of statistical models. Stat Med 1990;9:1305-25.
34. Hanley JA, Mc Neil BJ. The meaning and use of the area under a receiver operating characteristic (ROC) curve. Radiology 1982;143:29-36.
35. Bronner IM, Hoogendijk JE, Wintzen AR, van der Meulen MF, Linssen WH, Wokke JH, et al. Necrotising myopathy, an unusual presentation of a steroid-responsive myopathy. J Neurol 2003;250:480-5.
36. Vosskamper M, Korf K, Franke F, Schachenmayr W. Paraneoplastic necrotizing myopathy: a rare disorder to be differentiated from polymyositis. J Neurol 1989;236:489-90.
37. Ng Y, Ouvrier RA, Wu T. Drug therapy in juvenile dermatomyositis: follow-up study. J Child Neurol 1998;13:109-12.
38. Bernsen Spencer CH, Hanson V, Singsen BH, Bernstein BH, Kornreich HK, King KK. Course of treated juvenile dermatomyositis. J Pediatr 1984;105:399-408.
39. Bernsen RAJAM, de Jager AEJ, Schmitz PIM, van der Meché FGA. Long-term impact on work and private life after Guillain-Barré syndrome. J Neurol Sci 2002;201:13-17.
40. Bohan A, Peter JB. Polymyositis and dermatomyositis. N Engl J Med 1975;292:344-177, 403-7.